Preventative vs
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study
How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1
How you feel is a good indicator for how much your body might actually need
Two years ago, Jennifer Silver, 34, a dentist in Alberta, Canada, began taking a GLP-1 agonist medication to lose weight
GLP-1 medications have the potential to disrupt multiple points in that cycle simultaneously. And thats not all Research has established the protective effects of GLP-1 for the heart but we recently showed that the cardioprotective effects of GLP-1 drugs in patients at high risk of cardiovascular events are long-term and independent of diabetes status, indicating that they have the potential to be beneficial for patients who do not currently meet the prescription criteria, says Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University